tetrahydrocannabinol + cannabis

This investigational drug combination consists of delta-9-tetrahydrocannabinol (THC) within a cannabis plant matrix, specifically utilized in clinical research at the University of California, San Diego. The primary focus of its development in this context is to evaluate the interaction between cannabis use and antiretroviral therapy (ART) in individuals living with HIV. THC acts as a partial agonist of the CB1 and CB2 cannabinoid receptors, which are part of the endocannabinoid system. The research aims to assess how the drug affects the pharmacokinetics of ART, potentially influencing drug efficacy or toxicity, and to observe its impact on neurocognitive functions and mood in the HIV-positive population.

Other names

THC Cannabisdelta-9-tetrahydrocannabinoldelta9-tetrahydrocannabinoldelta 9-tetrahydrocannabinolmarijuana